"Designing Growth Strategies is in our DNA"
Chronic lymphocytic leukemia (CLL) is slow-growing cancer which begins in lymphocytes in the bone marrow and extends into the blood. It can even spread to lymph nodes and other organs such as spleen and liver. Chronic lymphocytic leukemia is divided into two types, B-cell chronic lymphocytic leukemia and T- cell chronic lymphocytic leukemia. Symptoms of chronic lymphocytic leukemia include enlarged lymph nodes, fever, fatigue, pain in the abdomen due to an enlarged spleen, weight loss, night sweats, frequent infections, and others.
In 2016, the American Cancer Society estimated that in the United States, about 18,960 new cases of chronic lymphocytic leukemia (CLL) and approximately 4,660 deaths by chronic lymphocytic leukemia (CLL) were reported. This rising prevalence and unmet patient needs have attracted many pharmaceutical industries to develop a novel treatment for chronic lymphocytic leukemia.
To gain extensive insights into the market, Request for Customization
Rising prevalence of chronic lymphocytic leukemia, rapid adoption of a sedentary lifestyle, and increasing aging population are the major factors driving the global chronic lymphocytic leukemia market. Also, an increased number of research and development in the oncology sector, new drug development, the introduction of novel therapies, and pipeline drug candidates are expected to fuel the global chronic lymphocytic leukemia therapeutics market.
However, the stringent government regulations and inadequate reimbursement policies in emerging countries are factors that can hamper the growth in the global chronic lymphocytic leukemia therapeutics market.
Some of the major companies that are present in the global chronic lymphocytic leukemia therapeutics market are Genzyme Corporation, Novartis International AG, Pfizer Inc., Roche Holding AG, Celgene Corporation, Ariad Pharmaceuticals Inc., Clavis Pharma ASA, and Sunesis Pharmaceuticals Inc., and others.
· Targeted Therapy
By Disease Indication
· B-cell Chronic Lymphocytic Leukemia
· T-cell Chronic Lymphocytic Leukemia
· Natural Killer Chronic Lymphocytic Leukemia
By Route of Administration
By Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Pharmacy
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Among the therapy, targeted therapy segment is anticipated to have a considerable growth over the forecast period, primarily due to the rapid adoption of targeted therapy, increased research, and the gradual shift of pharmaceutical companies towards the development of targeted therapy drugs.
North America is expected to dominate the global Chronic Lymphocytic Leukemia (CLL) market during the forecast period which can be attributed to the presence of potential pipeline candidates, and increased clinical studies for the development of novel treatment for chronic lymphocytic leukemia. In Europe, the Chronic Lymphocytic Leukemia (CLL) market is projected to expand due to the rising prevalence of Chronic Lymphocytic Leukemia (CLL) and strategic research collaborations. According to Cancer Research UK, it's estimated that around 3,800 new cases of chronic lymphocytic leukemia are diagnosed in the UK every year. Thus, the increasing incidences of chronic lymphocytic leukemia are also expected to boost the demand for chronic lymphocytic leukemia drugs in Europe. The Chronic lymphocytic leukemia (CLL) market in Asia Pacific is projected to have a significant growth in the forecast duration owing to the improving health reimbursement, growing focus towards pharmaemerging countries, and rising awareness about chronic lymphocytic leukemia.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry